In JO25567 trial, the addition of bevacizumab to erlotinib significantly prolonged PFS in NSCLC patients with EGFR mutation compared to erlotinib alone (median PFS: 16.0 vs. 9.7 months; P = 0.0015) [20]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.